About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2010 (2010), Article ID 306147, 3 pages
http://dx.doi.org/10.1155/2010/306147
Clinical Study

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)

Brooke Army Medical Center, MCHE MDC Cardiology Service, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200, USA

Received 28 September 2009; Revised 18 December 2009; Accepted 22 December 2009

Academic Editor: Gerhard M. Kostner

Copyright © 2010 Alan F. Helmbold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Bostom, L. A. Cupples, J. L. Jenner, et al., “Elevated plasma lipoprotein(a) and coronary heart disease in an aged 55 years and younger a prospective study,” The Journal of the American Medical Association, vol. 276, pp. 544–548, 1996.
  2. S. M. Marcovina, et al., “The effect of methodological differences in the measurement of Lp(a) on the interpretation of clinical data,” International Congress Series, vol. 1262, pp. 558–561, 2004.
  3. H. R. Superko and H. S. Hecht, “Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification,” American Journal of Cardiology, vol. 88, no. 3, pp. 260–264, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Dangas, R. Mehran, P. C. Harpel, et al., “Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation,” Journal of the American College of Cardiology, vol. 32, no. 7, pp. 2035–2042, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Stubbs, M. Seed, D. Lane, P. Collinson, F. Kendall, and M. Noble, “Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes,” European Heart Journal, vol. 19, no. 9, pp. 1355–1364, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Miles, G. M. Fless, E. G. Levin, A. M. Scanu, and E. F. Plow, “A potential basis for the thrombotic risks associated with lipoprotein(a),” Nature, vol. 339, no. 6222, pp. 301–303, 1989. View at Scopus
  7. D. I. Simon, G. M. Fless, A. M. Scanu, and J. Loscalzo, “Tissue type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein,” Biochemistry, vol. 30, pp. 6671–6677, 1991.
  8. J. Pan, M. Lin, R. L. Kesala, J. Van, and M. A. Charles, “Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes,” Diabetes, Obesity and Metabolism, vol. 4, no. 4, pp. 255–261, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Grundy, G. L. Vega, M. E. McGovern, et al., “Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial,” Archives of Internal Medicine, vol. 162, no. 14, pp. 1568–1576, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Herrmann, J. Biermann, and G. M. Kostner, “Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease,” American Journal of Cardiology, vol. 76, no. 7, pp. 459–462, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. F. U. Beil, W. Terres, M. Orgass, and H. Greten, “Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia,” Atherosclerosis, vol. 90, no. 1, pp. 95–97, 1991. View at Scopus
  12. O. Haglund, J. L. Mehta, and T. Saldeen, “Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects,” American Journal of Cardiology, vol. 74, no. 2, pp. 189–192, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Farnier, F. Bonnefous, N. Debbas, and A. Irvine, “Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia,” Archives of Internal Medicine, vol. 154, no. 4, pp. 441–449, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Dalessandri, “Multiple methods for reduction of lipoprotein(a),” Atherosclerosis, vol. 163, no. 2, pp. 409–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Akaiek, H. Azuma, A. Kagawa, et al., “Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases,” Clinical Chemistry, vol. 48, no. 9, pp. 1454–1459, 2002. View at Scopus
  16. K. M. Dalessandri, “Reduction of lipoprotein(a) in postmenopausal women,” Archives of Internal Medicine, vol. 161, no. 5, pp. 772–773, 2001. View at Scopus
  17. G. Derosa, A. F. Cicero, A. Gaddi, A. Mugellini, L. Ciccarelli, and R. Fogari, “The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus,” Clinical Therapeutics, vol. 25, no. 5, pp. 1429–1439, 2003.
  18. A. L. White and R. E. Lanford, “Biosynthesis and metabolism of lipoprotein(a),” Current Opinion in Lipidology, vol. 6, pp. 75–80, 1995.
  19. S. M. Marcovina and J. D. Morrisett, “Structure and metabolism of lipoprotein(a),” Current Opinion in Lipidology, vol. 6, pp. 136–145, 1995.
  20. J. Thiery, V. W. Armstrong, J. Schleef, C. Creutzfeldt, W. Creutzfeldt, and D. Seidel, “Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor,” Klinische Wochenschrift, vol. 66, no. 10, pp. 462–463, 1988. View at Publisher · View at Google Scholar · View at Scopus
  21. A. F. Helmbold, “Management of elevated lipoprotein(a) via initial dietary modification and omega 3 fatty acid supplements: a case report,” in Proceedings of the International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease, New York, NY, USA, July 2003.